News

WSBI is currently advancing its lead molecule, WSBI-711, which is an antibody against two TCISM targets into midstage pre-clinical testing. WSBI’s other TCISM antibody and orally-active small molecule

SurModics and Clinuvel are into a collaboration for the development of Clinuvel’s sustained release Scenesse (afamelanotide) implant formulation from several years. The implant is being developed as a

LANL also expects to develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform

As per the agreement, OctoPlus is expected to take up the responsibility to develop a controlled release version of a product that is currently in clinical development using

Aciont said that the goal of the project is to develop a safe and effective ocular iontophoresis drug delivery system for high molecular weight drugs or macromolecules to

As per the terms of the agreement, NINDS is expected to fully fund and carry out a double-blind, cross-over, placebo-controlled, Phase II clinical trial in patients with epilepsy,

Winston Pharma’s application is expected to be subject to a standard review with a Prescription Drug User Fee Act (PDUFA) date in the second half of 2011. Winston

N8295 is the novel component of Dynavax’s Universal Flu vaccine candidate. N8295 is a fusion protein comprised of NP and M2e, two highly conserved influenza antigens covalently linked

Divine Skin’s new division is expected to target both over-the-counter (OTC) and prescription drug sectors. Divine Skin claimed that its research conducted in hair loss and other common